¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"basal cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • mulberry cell
    ¿Àµð¼¼Æ÷
  • multinuclear giant cell
    ´ÙÇÙ°Å´ë¼¼Æ÷, ¹µÇÙ°Å´ë¼¼Æ÷
  • multipolar nerve cell
    ´Ù±Ø½Å°æ¼¼Æ÷, ¹µ±Ø½Å°æ¼¼Æ÷
  • myeloid cell
    °ñ¼ö¼¼Æ÷
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷
  • myoepithelial cell
    ±Ù(À°)»óÇǼ¼Æ÷
  • myoid cell
    ±Ù(À°)À¯»ç¼¼Æ÷
  • mantle cell lymphoma
    ¿ÜÅõ¼¼Æ÷¸²ÇÁÁ¾
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mast cell degranulation
    ºñ¸¸¼¼Æ÷Å»°ú¸³
  • mast cell disease
    ºñ¸¸¼¼Æ÷º´
  • mastoid air cell
    ²ÀÁö¹úÁý, À¯µ¹¹úÁý
  • matrix cell
    ¹ÙÅÁÁú¼¼Æ÷, ±âÁú¼¼Æ÷
  • memory B cell
    ±â¾ïB¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • plasma cell
    ÇüÁú¼¼Æ÷
  • pluripotential cell
    ´Ù´É¼º¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü¼¼Æ÷
  • polynucleated cell
    ¹µÇÙ¼¼Æ÷
  • prickle cell
    °¡½Ã¼¼Æ÷
  • primed cell
    ÃÊȸ°¨ÀÛ¼¼Æ÷
  • primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • principal cell
    ÁÖ¼¼Æ÷
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷, Á¶·Õ¹Ú¼¼Æ÷
  • pyramidal cell
    ÇǶó¹Ô¼¼Æ÷
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • red blood cell
    ÀûÇ÷±¸
  • reserve cell
    ¿¹ºñ¼¼Æ÷
  • residential cell
    Á¤ÁÖ¼¼Æ÷
  • resting cell
    ÈÞÁö±â¼¼Æ÷, Á¤Áö¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hypoxic cell
    Àú»ê¼Ò¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷°¨ÀÛÁ¦
  • i-cell disease
    I-¼¼Æ÷º´
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immortalized cell
    ¹«ÇÑÁõ½Ä¼¼Æ÷
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷.
  • immunodeficiency syndrome, cell mediated
    ¼¼Æ÷¸Å°³ ¸é¿ª°áÇÌ ÁõÈıº
  • immunologically committed cell
    ¸é¿ª°æÇè¼¼Æ÷(¡­ÌèúÐá¬øà).
  • immunologically competent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(¡­îêÌ«á¬øà).
  • immunologically performing cell
    ¸é¿ª¼öÇ༼Æ÷(¡­âÄú¼á¬øà).
  • indeterminate cell
    ºÎÁ¤Çü(ÜôïÒû¡) ¼¼Æ÷(á¬øà)
  • indifferent cell
    ¹«°ü¼¼Æ÷.
  • indirect cell division
    °£Á¢¼¼Æ÷ºÐ¿­.
  • inducer T cell
    À¯µµ T ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • cell interface
    ¼¼Æ÷»çÀ̸é, ¼¼Æ÷°£¸é (¡­ÊàØü).
  • cell junction
    ¼¼Æ÷°£¿¬Á¢(á¬øàÊàææïÈ)(°áÇÕ)
  • cell junction
    ¼¼Æ÷°æ°è, ¼¼Æ÷¿¬Á¢(¡­ææïÈ).
  • cell killing
    ¼¼Æ÷»ìÇØ
  • cell labelling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell like colloidal drop
    ¼¼Æ÷¾çÄÝ·ÎÀ̵å¾×Àû.
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line
    ¼¼Æ÷°è(á¬øàͧ).
  • cell line, established
    È®¸³¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell loss factor
    ¼¼Æ÷¼Ò½Ç°è¼ö
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell mass
    ¼¼Æ÷µ¢¾î¸®, ¼¼Æ÷±«
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
LCL Levinthal-Coles-Lillie [body]; lower confidence limit; lower control limit; lymphoblastoid cell line...
MCC mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr...
MCD magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ...
MCT manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp...
MCV mean cell volume; mean clinical value; mean corpuscular volume; median cell volume; motor conduction...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
DLCL B-diffuse large-cell lymphomas
LCL B-lymphoblastoid cell line
LCL lymphoblastoid cell
LCL B-lymphoid cell lines
BSCC Basaloid squamous cell carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • null cell
    ´­ ¼¼Æ÷
    B, T ¼¼Æ÷ Ç¥¸é Ç¥Áö¸¦ °¡ÁöÁö ¾ÊÀº ¸²ÇÁ±¸.
  • off-cell pause
    ²¨Áü ¼¼Æ÷ ÁßÁö
  • on-cell
    ÄÑÁü ¼¼Æ÷
  • osteoprogenitor cell
    °ñ Á¶»ó ¼¼Æ÷, »À Á¶»ó ¼¼Æ÷
    1. °ñÀÇ À¯¸® Ç¥¸é ȤÀº ±× ±Ùó¿¡¼­ º¼ ¼ö ÀÖ´Â ºñ±³Àû ¹ÌºÐÈ­µÈ ¼¼Æ÷·Î¼­, ¾î¶² ȯ°æ¿¡¼­´Â ¼¼Æ÷ ºÐ¿­ÇÏ¿© °ñ¾Æ¼¼Æ÷·Î ÀüȯµÇµç°¡ ȤÀº À¶ÇÕÇÏ¿© ÆÄ°ñ ¼¼Æ÷·Î µÇ±âµµ ÇÑ´Ù. 2. ÀÏ¹Ý °ÉÇÕ Á¶Á÷ÀÇ ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î °£Áú Á¶Á÷¿¡¼­ À¯·¡ÇÑ ¼¼Æ÷·Î¼­ À¯»ç ºÐ¿­ ´É·Â°ú »À ¼¼Æ÷·Î ºÐÈ­µÉ ¼ö ÀÖ´Â ´É·ÂÀ» °®°í ÀÖ´Ù. Áß°£¿± ¼¼Æ÷¿Í À¯»çÇϸç, ÇÙÀº ¿°±â¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÇ°í ¼¼Æ÷ÁúÀº ¾çÀÌ Àû¾î »ê¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÈ´Ù.
  • oxyntic cell
    »ê ºÐºñ¼º ¼¼Æ÷
    »ê ºÐºñ¼ºÀÇ À§º® ¼¼Æ÷¿Í °°ÀÌ »êÀ» ºÐºñÇÏ´Â ¼¼Æ÷.
  • oxyphil cell
    È£»ê¼º ¼¼Æ÷
  • oxyphilic cell
    È£»ê ¼¼Æ÷, È£»ê¼º ¼¼Æ÷
  • packed cell volume
    ÃæÀü ¼¼Æ÷ ¿ëÀû
  • packed red blood cell
    ³óÃà ÀûÇ÷±¸, ÃæÀü ÀûÇ÷±¸
    1. Ç÷¾×À» ¿ø½É ºÐ¸®ÇßÀ» ¶§ ¹Ù´Ú¿¡ ¹ÐÁýÇØ ÀÖ´Â °Í, ÃæÀü ÀûÇ÷±¸ ºÎÇǸ¦ Ç츶ÅäÅ©¸®Æ®¶óÇÑ´Ù. 2. hematocrit °ü¿¡ äÃëÇÑ ÀüÇ÷À» ÃÖ´ë·Î ¿ø½É ºÐ¸®ÇÏ¿© ¾ò¾îÁö´Â ÀûÇ÷±¸ÀÇ Ä§ÀüÃþ.
  • paneth cell
    È£»ê¼º °ú¸³ ¼¼Æ÷
  • papillary squamous cell carcinoma
    À¯µÎ»ó ÆíÆò »óÇÇ ¼¼Æ÷¾Ï
  • parafollicular cell
    ºÎ¿©Æ÷ ¼¼Æ÷
  • parasympathetic nerve cell
    ºÎ±³°¨ ½Å°æ ¼¼Æ÷
  • parietal cell
    º® ¼¼Æ÷, ¿Üº® ¼¼Æ÷, º®Ãø ¼¼Æ÷
    1. À§ÀåÀÇ À§Ã¼¹«¿¡ ÀÖ´Â ¼±ÀÇ neck°ú isthmus¿¡ ¸¹ÀÌ ºÐºñÇϸç, ¿°»êÀ» ºÐºñÇÑ´Ù. 2. À§¾× Áß ¿°»êÀÇ ¿øÃµÀÌ µÇ´Â Å« Ÿ¿ø»ó ¶Ç´Â Ãßü»óÀÇ ¼¼Æ÷. À§¼± º®À» µû¶ó »êÀçÇϰí, °¡´Ã¾îÁø ¾ç´ÜÀº ÁÖ¼¼Æ÷ »çÀÌ¿¡ ³¢¾î ÀÖ´Ù.
  • pericellular cell
    ¼¼Æ÷ ÁÖÀ§ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
globoid cell A large cell of mesodermal origin that is found clustered in the intracranial tissues in globoid cell leukodystrophy.
(05 Mar 2000)
globoid cell leukodystrophy <radiology> Dysmyelinating disease, autosomal recessive, usually presents by 1 yr, specific enzyme deficiency identified, rapid spontaneous nystagmus, poikilothermia
Synonym: Krabbe leukodystrophy
(12 Dec 1998)
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
virus-transformed cell A cell that has been genetically changed to a tumour cell, the change being subsequently tramsmitted to all descendent cell's; cell's transformed by oncornaviruses continue to produce virus in high concentration without being killed; DNA tumour virus-transformed cell's develop (along with other changes) tumour-associated antigens and rarely produce virus.
(05 Mar 2000)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
glomerulosa cell A cell of the zona glomerulosa of the adrenal cortex that is the source of aldosterone; the cell's are arranged in spherical or oval groups.
(05 Mar 2000)
cell <cell biology> An autonomous self replicating unit (in principle) that may constitute an organism (in the case of unicellular organisms) or be a sub unit of multicellular organisms in which individual cells may be more or less specialised differentiated) for particular functions.
The individual units from which tissues of the body are formed. All living organisms are composed of one or more cells.
(26 Mar 1998)
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
cell aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á